ImmuPharma plc (LON:IMM – Get Free Report) shares were up 16.9% during mid-day trading on Monday . The stock traded as high as GBX 4.95 ($0.06) and last traded at GBX 4.60 ($0.06). Approximately 15,705,875 shares traded hands during mid-day trading, a decline of 19% from the average daily volume of 19,462,320 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Price Performance
The stock has a market capitalization of £19.16 million, a PE ratio of -460.00 and a beta of 1.53. The stock’s fifty day moving average is GBX 1.75 and its 200-day moving average is GBX 1.73.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- What is a Low P/E Ratio and What Does it Tell Investors?
- MP Materials: Rare Earth Elements Powering the EV Boom
- 3 Best Fintech Stocks for a Portfolio Boost
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- CD Calculator: Certificate of Deposit Calculator
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
